EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease.

PubWeight™: 0.82‹?›

🔗 View Article (PMC 1974793)

Published in Int J Clin Pract on June 01, 2007

Authors

S Gauthier1, A Juby, B Rehel, R Schecter

Author Affiliations

1: Alzheimer's Disease Research Unit, McGill Centre for Studies of Aging, Montreal, QC, Canada. serge.gauthier@mcgill.ca

Articles cited by this

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ (1999) 5.36

Attention and executive deficits in Alzheimer's disease. A critical review. Brain (1999) 3.15

The spectrum of behavioral changes in Alzheimer's disease. Neurology (1996) 2.97

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol (2000) 1.98

Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol (1978) 1.82

The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J Am Geriatr Soc (1996) 1.33

Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology (2005) 1.27

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin (2005) 1.26

Anxiety and depressive disorders in adult children caring for demented parents. Psychol Aging (1991) 1.25

Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry (1996) 1.24

Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord (2002) 1.20

Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J Comp Neurol (2003) 0.95

The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract Suppl (2002) 0.92

A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study. Curr Med Res Opin (2006) 0.90

Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Drugs Aging (2001) 0.89

The ABC of Alzheimer's disease: behavioral symptoms and their treatment. Int Psychogeriatr (2002) 0.88

Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles. Brain Res (2005) 0.87

Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study. Curr Med Res Opin (2004) 0.86

Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol (1998) 0.83

Methodologic issues regarding outcome measures for clinical drug trials of psychiatric complications in dementia. J Geriatr Psychiatry Neurol (1995) 0.81

Theories behind existing scales for rating behavior in dementia. Int Psychogeriatr (1996) 0.79